P833 Cervical cancer risk in newly diagnosed ulcerative colitis: a nationwide population-based study

Abstract

Background The association between ulcerative colitis (UC) and increased risk of cervical cancer in women remains controversial. We investigated cervical cancer risk in South Korean UC patients using the Korean National Health Insurance (NHI) claims data. Methods UC definitions included both ICD-10 codes and UC-specific prescriptions. We analyzed incident cases diagnosed between 2006 and 2015. Age-matched women without UC (control group) were randomly selected from the general population (1:3 ratio). Hazard ratios (HRs), adjusted for different covariates, were calculated using multivariate Cox proportional hazard regression. In total, 12,632 and 36,797 women with and without UC, respectively, were enrolled. Results Cervical cancer developed in 0.21% (68 person-years) and 0.14% (172 person-years) of UC patients and controls, respectively. The HR (95% CI) of cervical cancer in the UC group, with reference to the control group, was 1.56 (0.97-2.50). HR, stratified by age, was significantly high in elderly UC patients (≥60 years) at 3.65 (1.54–8.66). In UC patients, old age (≥40 years) and low socioeconomic status were associated with increased cervical cancer risk. Conclusion Elderly UC patients had a higher incidence of cervical cancer than age-matched controls in Korea, suggesting that elderly patients with newly diagnosed UC should be screened for cervical cancer.

A Case of End-stage Post-Covid-19 Pulmonary Fibrosis in a Kenyan Hospital

“…Cases of PC19-PF have increasingly been reported in the literature from about two years since the onset of COVID-19, although CT scan evidence of lung fibrosis may appear much earlier in some patients [17]. A population-based study in Korea demonstrated that vaccination against COVID-19 decreased the incidence of post-COVID-19 interstitial lung disease (which includes PC19-PF), i.e., an incidence of 0.8 vs. 1.83 per 1000 person-years between the vaccination cohort and the controls, respectively [18]. Despite our patient being on pirfenidone 250 mg thrice daily since August 2022 (when the pulmonary fibrosis was first demonstrated on a CT scan), she has had progressive worsening of the pulmonary fibrosis until she's currently oxygen-dependent.…”